Hansa Biopharma AB Capital Reinvestment Ratio

Latest as of September 2020: 0.14x

Hansa Biopharma AB capital reinvestment ratio. Hansa Biopharma AB (HNSA) has a Capital Reinvestment Ratio of 0.14x as of September 2020, meaning it reinvests 0% of its operating cash flow (Skr4.83 Million) in capital expenditures (Skr683.00K). Check HNSA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.14x

Capex / Operating Cash Flow

Operating Cash Flow

Skr4.83 Million

SEK

Capital Expenditures

Skr683.00K

SEK

Data as of

Sep 2020

Most recent filing

Hansa Biopharma AB Capital Reinvestment Ratio by Year (None–None)

Hansa Biopharma AB capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see Hansa Biopharma AB cash flow conversion.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow